ReviewFrontiers in cellular and infection microbiology2017
Review in Frontiers in cellular and infection microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Tularemia Antimicrobial Treatment and Prophylaxis: CDC Recommendations for Naturally Acquired Infections and Bioterrorism Response - United States, 2025.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2025Guideline
- Histopathologic findings of tularemia lymphadenitis.Journal of hematopathology · 2026Article
- Immunological changes associated with the treatment of pneumonic tularaemia in marmosets.Frontiers in cellular and infection microbiology · 2026Article
- Animal modelling with theMicrobiology (Reading, England) · 2025Article
- Structure, identification and characterization of the RibD-enolase complex inbioRxiv : the preprint server for biology · 2025Article
- Neck Mass: Tularemia Misdiagnosed as a Possible Malignancy.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2025Article
- An evaluation of antibiotic options for the treatment of biothreat pathogens.Frontiers in antibiotics · 2025Review
- Thoracic manifestations of tularaemia: a case series.Infection · 2024Article
- Successful treatment of glandular tularemia with azithromycin in a pregnant woman in Austria.Infection · 2024Article
- Targeting Tularemia: Clinical, Laboratory, and Treatment Outcomes From an 11-year Retrospective Observational Cohort in Northern Sweden.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Observational
- Development, Strategies, and Challenges for Tularemia Vaccine.Current microbiology · 2024Review
- Antimicrobial Susceptibility of Francisella tularensis Isolates in the United States, 2009-2018.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Treatment Outcome of Severe Respiratory Type B Tularemia Using Fluoroquinolones.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Observational
- Article
- Marmosets as models of infectious diseases.Frontiers in cellular and infection microbiology · 2024Review
- Non-vaccinal prophylaxis of tularemia.Frontiers in microbiology · 2024Review
- Tolfenpyrad displaysMicrobiology spectrum · 2023Article
- Positive Francisella tularensis meningitis outcome despite delayed identification: a case report.Annals of clinical microbiology and antimicrobials · 2023Article
- The Brief Case: Suspicious Gram-Negative Coccobacilli-Francisella tularensis subsp.Journal of clinical microbiology · 2023Review
- Case Studies and Literature Review of Francisella tularensis-Related Prosthetic Joint Infection.Emerging infectious diseases · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antibiotic classes that are recommended for tularaemia treatment are the aminoglycosides, the fluoroquinolones and the tetracyclines. However, cure rates vary between 60 and 100% depending on the antibiotic used, the time to appropriate antibiotic therapy setup and its duration, and the presence of complications, such as lymph node suppuration. Thus, antibiotic susceptibility testing (AST) of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.